First safety test of 'Off-the-Shelf' immune cells to fight tough leukemia
NCT ID NCT04220684
Summary
This early-stage trial tested the safety of a new immune cell therapy for adults with acute myeloid leukemia that has come back or not responded to other treatments. Doctors gave patients natural killer (NK) cells from healthy donors to see if they could help the body fight the cancer without causing severe side effects. The main goal was to find the safest dose and understand how the body reacts to these donor cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Oregon Health & Science University
Portland, Oregon, 24344, United States
Conditions
Explore the condition pages connected to this study.